<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38202234</PMID><DateRevised><Year>2024</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Cannabinoids and the Endocannabinoid System in Early SARS-CoV-2 Infection and Long COVID-19-A Scoping Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">227</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13010227</ELocationID><Abstract><AbstractText>Coronavirus disease-19 (COVID-19) is a highly contagious illness caused by the SARS-CoV-2 virus. The clinical presentation of COVID-19 is variable, often including symptoms such as fever, cough, headache, fatigue, and an altered sense of smell and taste. Recently, post-acute "long" COVID-19 has emerged as a concern, with symptoms persisting beyond the acute infection. Vaccinations remain one of the most effective preventative methods against severe COVID-19 outcomes and the development of long-term COVID-19. However, individuals with underlying health conditions may not mount an adequate protective response to COVID-19 vaccines, increasing the likelihood of severe symptoms, hospitalization, and the development of long-term COVID-19 in high-risk populations. This review explores the potential therapeutic role of cannabinoids in limiting the susceptibility and severity of infection, both pre- and post-SARS-CoV-19 infection. Early in the SARS-CoV-19 infection, cannabinoids have been shown to prevent viral entry, mitigate oxidative stress, and alleviate the associated cytokine storm. Post-SARS-CoV-2 infection, cannabinoids have shown promise in treating symptoms associated with post-acute long COVID-19, including depression, anxiety, post-traumatic stress injury, insomnia, pain, and decreased appetite. While current research primarily focuses on potential treatments for the acute phase of COVID-19, there is a gap in research addressing therapeutics for the early and post-infectious phases. This review highlights the potential for future research to bridge this gap by investigating cannabinoids and the endocannabinoid system as a potential treatment strategy for both early and post-SARS-CoV-19 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Cassidy</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6780-3367</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, NS B3H 1X5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9670-6192</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Biophysics, Dalhousie University, Halifax, NS B3H 1X5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3040-0238</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, NS B3H 1X5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6419-9168</Identifier><AffiliationInfo><Affiliation>Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, NS B3H 1X5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Biophysics, Dalhousie University, Halifax, NS B3H 1X5, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">THC</Keyword><Keyword MajorTopicYN="N">cannabidiol</Keyword><Keyword MajorTopicYN="N">cannabinoids</Keyword><Keyword MajorTopicYN="N">viral infection</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>11</Day><Hour>7</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>11</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>11</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38202234</ArticleId><ArticleId IdType="pmc">PMC10779964</ArticleId><ArticleId IdType="doi">10.3390/jcm13010227</ArticleId><ArticleId IdType="pii">jcm13010227</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  WHO Coronavirus (COVID-19) Dashboard.  [(accessed on 2 July 2023)].  Available online:  https://data.who.int/dashboards/covid19/cases?n=c.</Citation></Reference><Reference><Citation>Public Health Agency of Canada . COVID-19 Vaccination in Canada. Public Health Agency of Canada; Ottawa, ON, Canada: 2023.</Citation></Reference><Reference><Citation>Anmar A.-T. Tixagevimab and Cilgavimab: Can We See More Recommendations for Monoclonal Antibodies beyond COVID-19 Vaccination. Disaster Med. Public Health Prep. 2022;16:2254&#x2013;2255. doi: 10.1017/dmp.2022.150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/dmp.2022.150</ArticleId><ArticleId IdType="pmc">PMC9304947</ArticleId><ArticleId IdType="pubmed">35672931</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH COVID-19 Treatment Guidelines Panel . Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health; Bethesda, MD, USA: 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Q., Wang B., Mao J. The pathogenesis and treatment of the &#x2018;Cytokine Storm&#x2019; in COVID-19. J. Infect. 2020;80:607&#x2013;613. doi: 10.1016/j.jinf.2020.03.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.037</ArticleId><ArticleId IdType="pmc">PMC7194613</ArticleId><ArticleId IdType="pubmed">32283152</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R., Fehr A.R., Zheng J., Wohlford-Lenane C., Abrahante J.E., Mack M., Sompallae R., McCray P.B., Meyerholz D.K., Perlman S. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J. Clin. Investig. 2019;129:3625&#x2013;3639. doi: 10.1172/JCI126363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI126363</ArticleId><ArticleId IdType="pmc">PMC6715373</ArticleId><ArticleId IdType="pubmed">31355779</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussman J.P. Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention. Front. Pharmacol. 2020;11:1169. doi: 10.3389/fphar.2020.01169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.01169</ArticleId><ArticleId IdType="pmc">PMC7406916</ArticleId><ArticleId IdType="pubmed">32848776</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiss C.S. Cannabinoids and viral infections. Pharmaceuticals. 2010;3:1873&#x2013;1886. doi: 10.3390/ph3061873.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph3061873</ArticleId><ArticleId IdType="pmc">PMC2903762</ArticleId><ArticleId IdType="pubmed">20634917</ArticleId></ArticleIdList></Reference><Reference><Citation>Csete J., Kamarulzaman A., Kazatchkine M., Altice F., Balicki M., Buxton J., Cepeda J., Comfort M., Goosby E., Goul&#xe3;o J., et al. Public health and international drug policy. Lancet. 2016;387:1427&#x2013;1480. doi: 10.1016/S0140-6736(16)00619-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00619-X</ArticleId><ArticleId IdType="pmc">PMC5042332</ArticleId><ArticleId IdType="pubmed">27021149</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabi F.A., Al Zoubi M.S., Al-Nasser A.D., Kasasbeh G.A., Salameh D.M. SARS-CoV-2 and coronavirus disease 2019: What we know so far. Pathogens. 2020;9:231. doi: 10.3390/pathogens9030231.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens9030231</ArticleId><ArticleId IdType="pmc">PMC7157541</ArticleId><ArticleId IdType="pubmed">32245083</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Zhong L., Deng J., Peng J., Dan H., Zeng X., Li T., Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral Sci. 2020;12:8. doi: 10.1038/s41368-020-0074-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41368-020-0074-x</ArticleId><ArticleId IdType="pmc">PMC7039956</ArticleId><ArticleId IdType="pubmed">32094336</ArticleId></ArticleIdList></Reference><Reference><Citation>van Breemen R.B., Muchiri R.N., Bates T.A., Weinstein J.B., Leier H.C., Farley S., Tafesse F.G. Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants. J. Nat. Prod. 2022;85:176&#x2013;184. doi: 10.1021/acs.jnatprod.1c00946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jnatprod.1c00946</ArticleId><ArticleId IdType="pmc">PMC8768006</ArticleId><ArticleId IdType="pubmed">35007072</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattnaik G.P., Chakraborty H. Entry Inhibitors: Efficient Means to Block Viral Infection. J. Membr. Biol. 2020;253:425&#x2013;444. doi: 10.1007/s00232-020-00136-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00232-020-00136-z</ArticleId><ArticleId IdType="pmc">PMC7456447</ArticleId><ArticleId IdType="pubmed">32862236</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster T.L., Pickering S., Neil S.J.D. Inhibiting the Ins and Outs of HIV replication: Cell-intrinsic antiretroviral restrictions at the plasma membrane. Front. Immunol. 2018;8:1853. doi: 10.3389/fimmu.2017.01853.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01853</ArticleId><ArticleId IdType="pmc">PMC5758531</ArticleId><ArticleId IdType="pubmed">29354117</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Cui Q., Caffrey M., Rong L., Du R. Small molecule inhibitors of influenza virus entry. Pharmaceuticals. 2021;14:587. doi: 10.3390/ph14060587.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14060587</ArticleId><ArticleId IdType="pmc">PMC8234048</ArticleId><ArticleId IdType="pubmed">34207368</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras E.M., Monreal I.A., Ruvalcaba M., Ortega V., Aguilar H.C. Antivirals targeting paramyxovirus membrane fusion. Curr. Opin. Virol. 2021;51:34&#x2013;47. doi: 10.1016/j.coviro.2021.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2021.09.003</ArticleId><ArticleId IdType="pmc">PMC8994020</ArticleId><ArticleId IdType="pubmed">34592709</ArticleId></ArticleIdList></Reference><Reference><Citation>Khomich O.A., Kochetkov S.N., Bartosch B., Ivanov A.V. Redox biology of respiratory viral infections. Viruses. 2018;10:392. doi: 10.3390/v10080392.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10080392</ArticleId><ArticleId IdType="pmc">PMC6115776</ArticleId><ArticleId IdType="pubmed">30049972</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardakas P., Skaperda Z., Tekos F., Kouretas D. ROS and COVID. Antioxidants. 2022;11:339. doi: 10.3390/antiox11020339.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox11020339</ArticleId><ArticleId IdType="pmc">PMC8868524</ArticleId><ArticleId IdType="pubmed">35204221</ArticleId></ArticleIdList></Reference><Reference><Citation>Duca L., Ottolenghi S., Coppola S., Rinaldo R., Dei Cas M., Rubino F.M., Paroni R., Samaja M., Chiumello D.A., Motta I. Differential redox state and iron regulation in chronic obstructive pulmonary disease, acute respiratory distress syndrome and coronavirus disease 2019. Antioxidants. 2021;10:1460. doi: 10.3390/antiox10091460.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10091460</ArticleId><ArticleId IdType="pmc">PMC8470076</ArticleId><ArticleId IdType="pubmed">34573092</ArticleId></ArticleIdList></Reference><Reference><Citation>Gain C., Song S., Angtuaco T., Satta S., Kelesidis T. The role of oxidative stress in the pathogenesis of infections with coronaviruses. Front. Microbiol. 2023;13:1111930. doi: 10.3389/fmicb.2022.1111930.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.1111930</ArticleId><ArticleId IdType="pmc">PMC9880066</ArticleId><ArticleId IdType="pubmed">36713204</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam M.S., Czajkowsky D.M. SARS-CoV-2 infection and oxidative stress: Pathophysiological insight into thrombosis and therapeutic opportunities. Cytokine Growth Factor Rev. 2022;63:44&#x2013;57. doi: 10.1016/j.cytogfr.2021.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2021.11.001</ArticleId><ArticleId IdType="pmc">PMC8591899</ArticleId><ArticleId IdType="pubmed">34836751</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen Dinh Cat A., Montezano A.C., Burger D., Touyz R.M. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxidants Redox Signal. 2013;19:1110&#x2013;1120. doi: 10.1089/ars.2012.4641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2012.4641</ArticleId><ArticleId IdType="pmc">PMC3771549</ArticleId><ArticleId IdType="pubmed">22530599</ArticleId></ArticleIdList></Reference><Reference><Citation>Atalay S., Jarocka-karpowicz I., Skrzydlewskas E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants. 2020;9:21. doi: 10.3390/antiox9010021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9010021</ArticleId><ArticleId IdType="pmc">PMC7023045</ArticleId><ArticleId IdType="pubmed">31881765</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajesh M., Mukhopadhyay P., B&#xe1;tkai S., Hask&#xf3; G., Liaudet L., Drel V.R., Obrosova I.G., Pacher P. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am. J. Physiol.&#x2013;Heart Circ. Physiol. 2007;293:H610&#x2013;H619. doi: 10.1152/ajpheart.00236.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00236.2007</ArticleId><ArticleId IdType="pmc">PMC2228254</ArticleId><ArticleId IdType="pubmed">17384130</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H., Mukhopadhyay P., Rajesh M., Patel V., Mukhopadhyay B., Gao B., Hask&#xf3; G., Pacher P. Cannabidiol attenuates cisplatin-Lnduced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J. Pharmacol. Exp. Ther. 2009;328:708&#x2013;714. doi: 10.1124/jpet.108.147181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.108.147181</ArticleId><ArticleId IdType="pmc">PMC2682269</ArticleId><ArticleId IdType="pubmed">19074681</ArticleId></ArticleIdList></Reference><Reference><Citation>Amini M.A., Karimi J., Talebi S.S., Piri H. The Association of COVID-19 and Reactive Oxygen Species Modulator 1 (ROMO1) with Oxidative Stress. Chonnam Med. J. 2022;58:1&#x2013;5. doi: 10.4068/cmj.2022.58.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.4068/cmj.2022.58.1.1</ArticleId><ArticleId IdType="pmc">PMC8813649</ArticleId><ArticleId IdType="pubmed">35169552</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajesh M., Mukhopadhyay P., B&#xe1;tkai S., Arif M., Varga Z.V., M&#xe1;ty&#xe1;s C., Paloczi J., Lehocki A., Hask&#xf3; G., Pacher P. Cannabinoid receptor 2 activation alleviates diabetes-induced cardiac dysfunction, inflammation, oxidative stress, and fibrosis. GeroScience. 2022;44:1727&#x2013;1741. doi: 10.1007/s11357-022-00565-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-022-00565-9</ArticleId><ArticleId IdType="pmc">PMC9213632</ArticleId><ArticleId IdType="pubmed">35460032</ArticleId></ArticleIdList></Reference><Reference><Citation>Basha R.H., Sankaranarayanan C. &#x3b2;-Caryophyllene, a natural sesquiterpene lactone attenuates hyperglycemia mediated oxidative and inflammatory stress in experimental diabetic rats. Chem. Biol. Interact. 2016;245:50&#x2013;58. doi: 10.1016/j.cbi.2015.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2015.12.019</ArticleId><ArticleId IdType="pubmed">26748309</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y.C., Bok E., Huh S.H., Park J.-Y., Yoon S.-H., Kim S.R., Kim Y.-S., Maeng S., Hyun Park S., Jin B.K. Cannabinoid Receptor Type 1 Protects Nigrostriatal Dopaminergic Neurons against MPTP Neurotoxicity by Inhibiting Microglial Activation. J. Immunol. 2011;187:6508&#x2013;6517. doi: 10.4049/jimmunol.1102435.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1102435</ArticleId><ArticleId IdType="pubmed">22079984</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia J., Ma L., Wu M., Zhang L., Zhang X., Zhai Q., Jiang T., Wang Q., Xiong L. Anandamide protects HT22 cells exposed to hydrogen peroxide by inhibiting CB1 receptor-mediated type 2 NADPH oxidase. Oxid. Med. Cell. Longev. 2014;2014:893516. doi: 10.1155/2014/893516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/893516</ArticleId><ArticleId IdType="pmc">PMC4127243</ArticleId><ArticleId IdType="pubmed">25136404</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., Xie C., Ma K., Shang K., Wang W., et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 2020;71:762&#x2013;768. doi: 10.1093/cid/ciaa248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa248</ArticleId><ArticleId IdType="pmc">PMC7108125</ArticleId><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Coomes E.A., Haghbayan H. Interleukin-6 in COVID-19: A systematic review and meta-analysis. Rev. Med. Virol. 2020;30:1&#x2013;9. doi: 10.1002/rmv.2141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2141</ArticleId><ArticleId IdType="pmc">PMC7460877</ArticleId><ArticleId IdType="pubmed">32845568</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryavanshi S.V., Zaiachuk M., Pryimak N., Kovalchuk I., Kovalchuk O. Cannabinoids Alleviate the LPS-Induced Cytokine Storm via Attenuating NLRP3 Inflammasome Signaling and TYK2-Mediated STAT3 Signaling Pathways In Vitro. Cells. 2022;11:1391. doi: 10.3390/cells11091391.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11091391</ArticleId><ArticleId IdType="pmc">PMC9103143</ArticleId><ArticleId IdType="pubmed">35563697</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed A., Alghetaa H.F.K., Miranda K., Wilson K., Singh N.P., Cai G., Putluri N., Nagarkatti P., Nagarkatti M. &#x394;9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression. Int. J. Mol. Sci. 2020;21:6244. doi: 10.3390/ijms21176244.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21176244</ArticleId><ArticleId IdType="pmc">PMC7503745</ArticleId><ArticleId IdType="pubmed">32872332</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry B.M., Lippi G. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports. J. Crit. Care. 2020;58:27&#x2013;28. doi: 10.1016/j.jcrc.2020.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2020.03.011</ArticleId><ArticleId IdType="pmc">PMC7118619</ArticleId><ArticleId IdType="pubmed">32279018</ArticleId></ArticleIdList></Reference><Reference><Citation>Khodadadi H., Salles &#xc9;.L., Jarrahi A., Chibane F., Costigliola V., Yu J.C., Vaibhav K., Hess D.C., Dhandapani K.M., Baban B. Cannabidiol Modulates Cytokine Storm in Acute Respiratory Distress Syndrome Induced by Simulated Viral Infection Using Synthetic RNA. Cannabis Cannabinoid Res. 2020;5:197&#x2013;201. doi: 10.1089/can.2020.0043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/can.2020.0043</ArticleId><ArticleId IdType="pmc">PMC7480719</ArticleId><ArticleId IdType="pubmed">32923657</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza M.G., De Lorenzo R., Conte C., Poletti S., Vai B., Bollettini I., Melloni E., Furlan R., Ciceri F., Rovere-Querini P., et al. Anxiety and depression in COVID-19 survivors. Brain. Behav. Immun. 2022;89:594&#x2013;600. doi: 10.1016/j.bbi.2020.07.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.07.037</ArticleId><ArticleId IdType="pmc">PMC7390748</ArticleId><ArticleId IdType="pubmed">32738287</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Luciano S., Geddes J.R., Harrison P.J. Bidirectional associations between COVID-19 and psychiatric disorder: Retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8:130&#x2013;140. doi: 10.1016/S2215-0366(20)30462-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30462-4</ArticleId><ArticleId IdType="pmc">PMC7820108</ArticleId><ArticleId IdType="pubmed">33181098</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderheiden A., Klein R.S. Neuroinflammation and COVID-19. Curr. Opin. Neurobiol. 2022;76:102608. doi: 10.1016/j.conb.2022.102608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2022.102608</ArticleId><ArticleId IdType="pmc">PMC9239981</ArticleId><ArticleId IdType="pubmed">35863101</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou S., Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int. J. Mol. Sci. 2018;19:833. doi: 10.3390/ijms19030833.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19030833</ArticleId><ArticleId IdType="pmc">PMC5877694</ArticleId><ArticleId IdType="pubmed">29533978</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooray R., Gupta V., Suphioglu C. Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson&#x2019;s and Alzheimer&#x2019;s Diseases: A Review. Mol. Neurobiol. 2020;57:4878&#x2013;4890. doi: 10.1007/s12035-020-02054-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02054-6</ArticleId><ArticleId IdType="pmc">PMC7515854</ArticleId><ArticleId IdType="pubmed">32813239</ArticleId></ArticleIdList></Reference><Reference><Citation>Feingold D., Weinstein A. Advances in Experimental Medicine and Biology. Volume 1264 Springer; Cham, Switzerland: 2021. Cannabis and Depression.</Citation><ArticleIdList><ArticleId IdType="pubmed">33332004</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristino L., Bisogno T., Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat. Rev. Neurol. 2020;16:9&#x2013;29. doi: 10.1038/s41582-019-0284-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0284-z</ArticleId><ArticleId IdType="pubmed">31831863</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettman C.K., Abdalla S.M., Cohen G.H., Sampson L., Vivier P.M., Galea S. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Netw. Open. 2020;3:e2019686. doi: 10.1001/jamanetworkopen.2020.19686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.19686</ArticleId><ArticleId IdType="pmc">PMC7489837</ArticleId><ArticleId IdType="pubmed">32876685</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankelevitch-yahav R., Franko M., Huly A., Doron R. The Forced Swim Test as a Model of Depressive-like Behavior. J. Vis. Exp. 2015;17:e52587. doi: 10.3791/52587.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/52587</ArticleId><ArticleId IdType="pmc">PMC4401172</ArticleId><ArticleId IdType="pubmed">25867960</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanelati T.V., Biojone C., Moreira F.A., Guimar&#xe3;es F.S., Joca S.R.L. Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors. Br. J. Pharmacol. 2010;159:122&#x2013;128. doi: 10.1111/j.1476-5381.2009.00521.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2009.00521.x</ArticleId><ArticleId IdType="pmc">PMC2823358</ArticleId><ArticleId IdType="pubmed">20002102</ArticleId></ArticleIdList></Reference><Reference><Citation>Sartim A.G., Guimar&#xe3;es F.S., Joca S.R.L. Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex&#x2014;Possible involvement of 5-HT1A and CB1 receptors. Behav. Brain Res. 2016;303:218&#x2013;227. doi: 10.1016/j.bbr.2016.01.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2016.01.033</ArticleId><ArticleId IdType="pubmed">26801828</ArticleId></ArticleIdList></Reference><Reference><Citation>Silote G.P., Gatto M.C., Eskelund A., Guimar&#xe3;es F.S., Wegener G., Joca S.R.L. Strain-, Sex-, and Time-Dependent Antidepressant-like Effects of Cannabidiol. Pharmaceuticals. 2021;14:1269. doi: 10.3390/ph14121269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14121269</ArticleId><ArticleId IdType="pmc">PMC8709491</ArticleId><ArticleId IdType="pubmed">34959670</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin E.L., Strickland J.C., Schlienz N.J., Munson J., Jackson H., Bonn-miller M.O., Vandrey R. Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial. Front. Psychiatry. 2021;12:1554. doi: 10.3389/fpsyt.2021.729800.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2021.729800</ArticleId><ArticleId IdType="pmc">PMC8458732</ArticleId><ArticleId IdType="pubmed">34566726</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangoo S., Erridge S., Holvey C., Coomber R., Barros D.A.R., Bhoskar U., Mwimba G., Praveen K., Symeon C., Sachdeva-Mohan S., et al. Assessment of clinical outcomes of medicinal cannabis therapy for depression: Analysis from the UK Medical Cannabis Registry. Expert Rev. Neurother. 2022;22:995&#x2013;1008. doi: 10.1080/14737175.2022.2161894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2022.2161894</ArticleId><ArticleId IdType="pubmed">36573268</ArticleId></ArticleIdList></Reference><Reference><Citation>Empower Research Inc. Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids. Empower Research Inc.; New York, NY, USA: 2021. NCT04965740.</Citation></Reference><Reference><Citation>Scherma M., Lisa Muntoni A., Riedel G., Fratta W., Fadda P. Cannabinoids and their therapeutic applications in mental disorders. Dialogues Clin. Neurosci. 2020;22:271&#x2013;279. doi: 10.31887/DCNS.2020.22.3/pfadda.</Citation><ArticleIdList><ArticleId IdType="doi">10.31887/DCNS.2020.22.3/pfadda</ArticleId><ArticleId IdType="pmc">PMC7605020</ArticleId><ArticleId IdType="pubmed">33162770</ArticleId></ArticleIdList></Reference><Reference><Citation>Bovasso G.B. Cannabis Abuse as a Risk Factor for Depressive Symptoms. Am. J. Psychiatry. 2001;158:2033&#x2013;2037. doi: 10.1176/appi.ajp.158.12.2033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.158.12.2033</ArticleId><ArticleId IdType="pubmed">11729021</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.S.K., Clough A.R., Jaragba M.J., Conigrave K.M., Patton G.C. Heavy cannabis use and depressive symptoms in three Aboriginal communities in Arnhem Land, Northern Territory. Med. J. Aust. 2008;188:605&#x2013;608. doi: 10.5694/j.1326-5377.2008.tb01803.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/j.1326-5377.2008.tb01803.x</ArticleId><ArticleId IdType="pubmed">18484938</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherma M., Masia P., Deidda M., Fratta W., Tanda G., Fadda P. New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders. Medicines. 2018;5:107. doi: 10.3390/medicines5040107.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicines5040107</ArticleId><ArticleId IdType="pmc">PMC6313625</ArticleId><ArticleId IdType="pubmed">30279403</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Maldonado R., Caba&#xf1;ero D., Mart&#xed;n-Garc&#xed;a E. The endocannabinoid system in modulating fear, anxiety, and stress. Dialogues Clin. Neurosci. 2020;22:229&#x2013;239. doi: 10.31887/DCNS.2020.22.3/rmaldonado.</Citation><ArticleIdList><ArticleId IdType="doi">10.31887/DCNS.2020.22.3/rmaldonado</ArticleId><ArticleId IdType="pmc">PMC7605023</ArticleId><ArticleId IdType="pubmed">33162766</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes F.V., Resstel L.B.M., Guimar&#xe3;es F.S. The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology. 2011;213:465&#x2013;473. doi: 10.1007/s00213-010-2036-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-010-2036-z</ArticleId><ArticleId IdType="pubmed">20945065</ArticleId></ArticleIdList></Reference><Reference><Citation>Resstel L.B.M., Joca S.R.L., Moreira F.A., Corr&#xea;a F.M.A., Guimar&#xe3;es F.S. Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behav. Brain Res. 2006;172:294&#x2013;298. doi: 10.1016/j.bbr.2006.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2006.05.016</ArticleId><ArticleId IdType="pubmed">16780966</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira F.A., Aguiar D.C., Guimar&#xe3;es F.S. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2006;30:1466&#x2013;1471. doi: 10.1016/j.pnpbp.2006.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2006.06.004</ArticleId><ArticleId IdType="pubmed">16876926</ArticleId></ArticleIdList></Reference><Reference><Citation>Onaivi E.S., Green M.R., Martin B.R. Pharmacological characterization of cannabinoids in the elevated plus maze. J. Pharmacol. Exp. Ther. 1990;253:1003&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">2162942</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimar&#xe3;es F.S., Chiaretti T.M., Graeff F.G., Zuardi A.W. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology. 1990;100:558&#x2013;559. doi: 10.1007/BF02244012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02244012</ArticleId><ArticleId IdType="pubmed">1969666</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuardi A.W., Cosme R.A., Graeff F.G., Guimar&#xe3;es F.S. Effects of ipsapirone and cannabidiol on human experimental anxiety. J. Psychopharmacol. 1993;7:82&#x2013;83. doi: 10.1177/026988119300700112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/026988119300700112</ArticleId><ArticleId IdType="pubmed">22290374</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi M.M., Helena R., Queiroz C., Hortes M., Chagas N., Roesler R., Schro N., Crippa A.S., Zuardi A.W. Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Na&#xef;ve Social Phobia Patients. Neuropsychopharmacology. 2011;36:1219&#x2013;1226. doi: 10.1038/npp.2011.6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2011.6</ArticleId><ArticleId IdType="pmc">PMC3079847</ArticleId><ArticleId IdType="pubmed">21307846</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Sullivan S.E., Stevenson C.W., Laviolette S.R. Could cannabidiol be a treatment for coronavirus disease-19-related anxiety disorders? Cannabis Cannabinoid Res. 2021;6:7&#x2013;18. doi: 10.1089/can.2020.0102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/can.2020.0102</ArticleId><ArticleId IdType="pmc">PMC7891214</ArticleId><ArticleId IdType="pubmed">33614948</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertz Schou T., Joca S., Wegener G., Bay-richter C. Psychiatric and neuropsychiatric sequelae of COVID-19&#x2014;A systematic review. Brain Behav. Immun. 2021;97:328&#x2013;348. doi: 10.1016/j.bbi.2021.07.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.07.018</ArticleId><ArticleId IdType="pmc">PMC8363196</ArticleId><ArticleId IdType="pubmed">34339806</ArticleId></ArticleIdList></Reference><Reference><Citation>Roitman P., Mechoulam R., Cooper-Kazaz R., Shalev A. Preliminary, open-label, pilot study of add-on oral &#x394;9- tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin. Drug Investig. 2014;34:587&#x2013;591. doi: 10.1007/s40261-014-0212-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40261-014-0212-3</ArticleId><ArticleId IdType="pubmed">24935052</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron C., Watson D., Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: A retrospective evaluation. J. Clin. Psychopharmacol. 2014;34:559&#x2013;564. doi: 10.1097/JCP.0000000000000180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JCP.0000000000000180</ArticleId><ArticleId IdType="pmc">PMC4165471</ArticleId><ArticleId IdType="pubmed">24987795</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser G.A. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD) CNS Neurosci. Ther. 2009;15:84&#x2013;88. doi: 10.1111/j.1755-5949.2008.00071.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-5949.2008.00071.x</ArticleId><ArticleId IdType="pmc">PMC6494011</ArticleId><ArticleId IdType="pubmed">19228182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardo M.D.M., Foppiani A., Peretti G.M., Mangiavini L., Battezzati A., Bertoli S., Martinelli Boneschi F., Zuccotti G.V. Long-Term Coronavirus Disease 2019 Complications in Inpatients and Outpatients: A One-Year Follow-up Cohort Study. Open Forum Infect. Dis. 2021;8:ofab384. doi: 10.1093/ofid/ofab384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab384</ArticleId><ArticleId IdType="pmc">PMC8344801</ArticleId><ArticleId IdType="pubmed">34386546</ArticleId></ArticleIdList></Reference><Reference><Citation>Murillo-Rodr&#xed;guez E. The role of the CB1 receptor in the regulation of sleep. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2008;32:1420&#x2013;1427. doi: 10.1016/j.pnpbp.2008.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2008.04.008</ArticleId><ArticleId IdType="pubmed">18514375</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh J.H., Maddison K.J., Rankin T., Murray K., McArdle N., Ree M.J., Hillman D.R., Eastwood P.R. Treating insomnia symptoms with medicinal cannabis: A randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo. Sleep. 2021;44:zsab149. doi: 10.1093/sleep/zsab149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/zsab149</ArticleId><ArticleId IdType="pmc">PMC8598183</ArticleId><ArticleId IdType="pubmed">34115851</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykes D.L., Holdsworth L., Jawad N., Gunasekera P., Morice A.H., Crooks M.G. Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It? Lung. 2021;199:113&#x2013;119. doi: 10.1007/s00408-021-00423-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-021-00423-z</ArticleId><ArticleId IdType="pmc">PMC7875681</ArticleId><ArticleId IdType="pubmed">33569660</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya J., Rojas M., Salinas M.L., Rodr&#xed;guez Y., Roa G., Lozano M., Rodr&#xed;guez-Jim&#xe9;nez M., Montoya N., Zapata E., Monsalve D.M., et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun. Rev. 2021;20:102947. doi: 10.1016/j.autrev.2021.102947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102947</ArticleId><ArticleId IdType="pmc">PMC8428988</ArticleId><ArticleId IdType="pubmed">34509649</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruni N., Della Pepa C., Oliaro-Bosso S., Pessione E., Gastaldi D., Dosio F. Cannabinoid delivery systems for pain and inflammation treatment. Molecules. 2018;23:2478. doi: 10.3390/molecules23102478.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules23102478</ArticleId><ArticleId IdType="pmc">PMC6222489</ArticleId><ArticleId IdType="pubmed">30262735</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala K., Martens J., Abd-Elsayed A. Post-COVID Pain Syndromes. Curr. Pain Headache Rep. 2022;26:379&#x2013;383. doi: 10.1007/s11916-022-01038-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11916-022-01038-6</ArticleId><ArticleId IdType="pmc">PMC8907389</ArticleId><ArticleId IdType="pubmed">35267156</ArticleId></ArticleIdList></Reference><Reference><Citation>Malan P.T., Ibrahim M.M., Deng H., Liu Q., Mata H.P., Vanderah T., Porreca F., Makriyannis A. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain. 2001;93:239&#x2013;245. doi: 10.1016/S0304-3959(01)00321-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3959(01)00321-9</ArticleId><ArticleId IdType="pubmed">11514083</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin W.J., Tsou K., Walker J.M. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci. Lett. 1998;242:33&#x2013;36. doi: 10.1016/S0304-3940(98)00044-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(98)00044-5</ArticleId><ArticleId IdType="pubmed">9509998</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris H.M., Rousseau M.A., Wanas A.S., Radwan M.M., Caldwell S., Sufka K.J., Elsohly M.A. Role of Cannabinoids and Terpenes in Cannabis-Mediated Analgesia in Rats. Cannabis Cannabinoid Res. 2019;4:177&#x2013;182. doi: 10.1089/can.2018.0054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/can.2018.0054</ArticleId><ArticleId IdType="pmc">PMC6757239</ArticleId><ArticleId IdType="pubmed">31579834</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilsey B., Marcotte T., Deutsch R., Gouaux B., Sakai S., Donaghe H. Low Dose Vaporized Cannabis Significantly Improves Neuropathic Pain. J. Pain. 2013;14:136&#x2013;148. doi: 10.1016/j.jpain.2012.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpain.2012.10.009</ArticleId><ArticleId IdType="pmc">PMC3566631</ArticleId><ArticleId IdType="pubmed">23237736</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilsey B., Marcotte T., Deutsch R., Zhao H., Prasad H., Phan A. An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain from Spinal Cord Injury and Disease. J. Pain. 2016;17:982&#x2013;1000. doi: 10.1016/j.jpain.2016.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpain.2016.05.010</ArticleId><ArticleId IdType="pmc">PMC5007175</ArticleId><ArticleId IdType="pubmed">27286745</ArticleId></ArticleIdList></Reference><Reference><Citation>Romeyke T., Westfal R. Integration of Cannabis Extract Tetrahydrocannabinol:Cannabidiol in an Interdisciplinary Therapy Setting: A Case of Chronic Multilocular Pain Disorder. Med. Cannabis Cannabinoids. 2022;5:220&#x2013;225. doi: 10.1159/000527521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000527521</ArticleId><ArticleId IdType="pmc">PMC9710317</ArticleId><ArticleId IdType="pubmed">36467780</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurmikko T.J., Serpell M.G., Hoggart B., Toomey P.J., Morlion B.J., Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133:210&#x2013;220. doi: 10.1016/j.pain.2007.08.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2007.08.028</ArticleId><ArticleId IdType="pubmed">17997224</ArticleId></ArticleIdList></Reference><Reference><Citation>Pini L.A., Guerzoni S., Cainazzo M.M., Ferrari A., Sarchielli P., Tiraferri I., Ciccarese M., Zappaterra M. Nabilone for the treatment of medication overuse headache: Results of a preliminary double-blind, active-controlled, randomized trial. J. Headache Pain. 2012;13:677&#x2013;684. doi: 10.1007/s10194-012-0490-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10194-012-0490-1</ArticleId><ArticleId IdType="pmc">PMC3484259</ArticleId><ArticleId IdType="pubmed">23070400</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinsger M., Schimetta W., Volc D., Hiermann E., Riederer F., P&#xf6;lz W. 624 Benefits of an Add-On Treatment with the Synthetic Cannabinomimetic Nabilone on Patients with Chronic Pain&#x2014;A Randomized Controlled Trial. Eur. J. Pain. 2006;10:S163&#x2013;S164. doi: 10.1016/S1090-3801(06)60627-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1090-3801(06)60627-7</ArticleId><ArticleId IdType="pubmed">16855921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueberall M.A., Vila Silv&#xe1;n C., Essner U., Mueller-Schwefe G.H.H. Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry. Pain Med. 2022;23:745&#x2013;760. doi: 10.1093/pm/pnab263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pm/pnab263</ArticleId><ArticleId IdType="pmc">PMC8992580</ArticleId><ArticleId IdType="pubmed">34480564</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik Z., Bayman L., Valestin J., Rizvi-Toner A., Hashmi S., Schey R. Dronabinol increases pain threshold in patients with functional chest pain: A pilot double-blind placebo-controlled trial. Dis. Esophagus. 2017;30:1&#x2013;8. doi: 10.1111/dote.12455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dote.12455</ArticleId><ArticleId IdType="pubmed">26822791</ArticleId></ArticleIdList></Reference><Reference><Citation>Lal S., Prasad N., Ryan M., Tangri S., Silverberg M.S., Gordon A., Steinhart H. Cannabis use amongst patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 2011;23:891&#x2013;896. doi: 10.1097/MEG.0b013e328349bb4c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0b013e328349bb4c</ArticleId><ArticleId IdType="pubmed">21795981</ArticleId></ArticleIdList></Reference><Reference><Citation>Allegretti J.R., Courtwright A., Lucci M., Korzenik J.R., Levine J. Marijuana use patterns among patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2013;19:2809&#x2013;2814. doi: 10.1097/01.MIB.0000435851.94391.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.MIB.0000435851.94391.37</ArticleId><ArticleId IdType="pmc">PMC4126607</ArticleId><ArticleId IdType="pubmed">24185313</ArticleId></ArticleIdList></Reference><Reference><Citation>Phatak U.P., Rojas-Velasquez D., Porto A., Pashankar D.S. Prevalence and Patterns of Marijuana Use in Young Adults with Inflammatory Bowel Disease. J. Pediatr. Gastroenterol. Nutr. 2017;64:261&#x2013;264. doi: 10.1097/MPG.0000000000001474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001474</ArticleId><ArticleId IdType="pubmed">27846066</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffenberg E.J., McWilliams S.K., Mikulich-Gilbertson S.K., Murphy B.V., Lagueux M., Robbins K., Hoffenberg A.S., de Zoeten E., Hopfer C.J. Marijuana Use by Adolescents and Young Adults with Inflammatory Bowel Disease. J. Pediatr. 2018;199:99&#x2013;105. doi: 10.1016/j.jpeds.2018.03.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2018.03.041</ArticleId><ArticleId IdType="pubmed">29673723</ArticleId></ArticleIdList></Reference><Reference><Citation>Storr M., Devlin S., Kaplan G.G., Panaccione R., Andrews C.N. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn&#x2019;s disease. Inflamm. Bowel Dis. 2014;20:472&#x2013;480. doi: 10.1097/01.MIB.0000440982.79036.d6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.MIB.0000440982.79036.d6</ArticleId><ArticleId IdType="pubmed">24407485</ArticleId></ArticleIdList></Reference><Reference><Citation>Naftali T., Lev L.B., Yablekovitz D., Half E., Konikoff F.M. Treatment of Crohn&#x2019;s disease with Cannabis: An observational study. Isr. Med. Assoc. J. 2011;13:455&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">21910367</ArticleId></ArticleIdList></Reference><Reference><Citation>Naftali T., Bar-Lev Schleider L., Dotan I., Lansky E.P., Sklerovsky Benjaminov F., Konikoff F.M. Cannabis induces a clinical response in patients with crohn&#x2019;s disease: A prospective placebo-controlled study. Clin. Gastroenterol. Hepatol. 2013;11:1276&#x2013;1280. doi: 10.1016/j.cgh.2013.04.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2013.04.034</ArticleId><ArticleId IdType="pubmed">23648372</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuill M.B., Hale D.E., Guindon J., Morgan D.J. Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain. Mol. Pain. 2017;13:1&#x2013;15. doi: 10.1177/1744806917728227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1744806917728227</ArticleId><ArticleId IdType="pmc">PMC5593227</ArticleId><ArticleId IdType="pubmed">28879802</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh G.C., Pai M., Chandran P., Hooker B.A., Zhu C.Z., Salyers A.K., Wensink E.J., Zhan C., Carroll W.A., Dart M.J., et al. Central and peripheral sites of action for CB 2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br. J. Pharmacol. 2011;162:428&#x2013;440. doi: 10.1111/j.1476-5381.2010.01046.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2010.01046.x</ArticleId><ArticleId IdType="pmc">PMC3031063</ArticleId><ArticleId IdType="pubmed">20880025</ArticleId></ArticleIdList></Reference><Reference><Citation>Rog D.J., Nurmikko T.J., Friede T., Young C.A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812&#x2013;819. doi: 10.1212/01.wnl.0000176753.45410.8b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000176753.45410.8b</ArticleId><ArticleId IdType="pubmed">16186518</ArticleId></ArticleIdList></Reference><Reference><Citation>Svendsen K.B., Jensen T.S., Bach F.W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329:253. doi: 10.1136/bmj.38149.566979.AE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.38149.566979.AE</ArticleId><ArticleId IdType="pmc">PMC498019</ArticleId><ArticleId IdType="pubmed">15258006</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake D.R., Robson P., Ho M., Jubb R.W., McCabe C.S. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology. 2006;45:50&#x2013;52. doi: 10.1093/rheumatology/kei183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kei183</ArticleId><ArticleId IdType="pubmed">16282192</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury A., Tariq R., Jena A., Kinzelman Vesely E., Singh S., Khanna S., Sharma V. Gastrointestinal manifestations of long COVID: A systematic review and meta-analysis. Ther. Adv. Vaccines. 2022;15:1&#x2013;18. doi: 10.1177/17562848221118403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17562848221118403</ArticleId><ArticleId IdType="pmc">PMC9393939</ArticleId><ArticleId IdType="pubmed">36004306</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Guo C., Tang L., Hong Z., Zhou J., Dong X., Yin H., Xiao Q., Tang Y., Qu X., et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol. Hepatol. 2020;5:434&#x2013;435. doi: 10.1016/S2468-1253(20)30083-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30083-2</ArticleId><ArticleId IdType="pmc">PMC7158584</ArticleId><ArticleId IdType="pubmed">32199469</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting P.F., Wolff R.F., Deshpande S., Di Nisio M., Duffy S., Hernandez A.V., Keurentjes J.C., Lang S., Misso K., Ryder S., et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 2015;313:2456&#x2013;2473. doi: 10.1001/jama.2015.6358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.6358</ArticleId><ArticleId IdType="pubmed">26103030</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleckner A., Kleckner I., Kamen C., Tejani M., Janelsins M., Morrow G., Pepponee L. Opportunities for cannabis in supportive care in cancer. Ther. Adv. Med. Oncol. 2019;11:1&#x2013;29. doi: 10.1177/1758835919866362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1758835919866362</ArticleId><ArticleId IdType="pmc">PMC6676264</ArticleId><ArticleId IdType="pubmed">31413731</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng J., Li Y., Li J., Shen L., Zhu L., Liang Y., Lin X., Jiao N., Cheng S., Huang Y., et al. Gastrointestinal sequelae 90 days after discharge for COVID-19. Lancet Gastroenterol. Hepatol. 2021;6:344&#x2013;346. doi: 10.1016/S2468-1253(21)00076-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(21)00076-5</ArticleId><ArticleId IdType="pmc">PMC7943402</ArticleId><ArticleId IdType="pubmed">33711290</ArticleId></ArticleIdList></Reference><Reference><Citation>Meiri E., Jhangiani H., Vredenburgh J.J., Barbato L.M., Carter F.J., Yang H.M., Baranowski V. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr. Med. Res. Opin. 2007;23:533&#x2013;543. doi: 10.1185/030079907X167525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1185/030079907X167525</ArticleId><ArticleId IdType="pubmed">17355735</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith L.A., Azariah F., Lavender V.T., Stoner N.S., Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst. Rev. 2015;2015:CD009464. doi: 10.1002/14651858.CD009464.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009464.pub2</ArticleId><ArticleId IdType="pmc">PMC6931414</ArticleId><ArticleId IdType="pubmed">26561338</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado Rocha F.C., St&#xe9;fano S.C., De C&#xe1;ssia Haiek R., Rosa Oliveira L.M.Q., Da Silveira D.X. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: Systematic review and meta-analysis. Eur. J. Cancer Care. 2008;17:431&#x2013;443. doi: 10.1111/j.1365-2354.2008.00917.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2354.2008.00917.x</ArticleId><ArticleId IdType="pubmed">18625004</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson D.L.B., Campbell M., Hopkins C., Smith B., Kelly C., Deary V. Altered smell and taste: Anosmia, parosmia and the impact of long COVID-19. PLoS ONE. 2021;16:e0256998. doi: 10.1371/journal.pone.0256998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0256998</ArticleId><ArticleId IdType="pmc">PMC8462678</ArticleId><ArticleId IdType="pubmed">34559820</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkham T.C. Endocannabinoids in the regulation of appetite and body weight. Behav. Pharmacol. 2005;16:297&#x2013;313. doi: 10.1097/00008877-200509000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00008877-200509000-00004</ArticleId><ArticleId IdType="pubmed">16148436</ArticleId></ArticleIdList></Reference><Reference><Citation>Dipatrizio N.V., Ja T.U.C. &#x394;9-THC induced hyperphagia and tolerance assessment: Interactions between the CB1 receptor agonist &#x394;9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats. Behav. Pharmacol. 2005;16:373&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">16148441</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal J.E., Olson R., Laubenstein L., Morales J.O., Bellman P., Yangco B., Lefkowitz L., Plasse T.F., Shepard K.V. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom Manag. 1995;10:89&#x2013;97. doi: 10.1016/0885-3924(94)00117-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0885-3924(94)00117-4</ArticleId><ArticleId IdType="pubmed">7730690</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilbao A., Spanagel R., Medicine M.C. Medical cannabinoids: A pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med. 2022;20:259. doi: 10.1186/s12916-022-02459-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02459-1</ArticleId><ArticleId IdType="pmc">PMC9389720</ArticleId><ArticleId IdType="pubmed">35982439</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiplo S., Asbridge M., Leatherdale S.T., Hammond D. Medical cannabis use in Canada: Vapourization and modes of delivery. Harm Reduct. J. 2016;13:30. doi: 10.1186/s12954-016-0119-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12954-016-0119-9</ArticleId><ArticleId IdType="pmc">PMC5086046</ArticleId><ArticleId IdType="pubmed">27793174</ArticleId></ArticleIdList></Reference><Reference><Citation>Penzel N., Antonucci L.A., Betz L.T., Sanfelici R., Weiske J., Pogarell O., Cumming P., Quednow B.B., Howes O., Falkai P., et al. Association between age of cannabis initiation and gray matter covariance networks in recent onset psychosis. Neuropsychopharmacology. 2021;46:1484&#x2013;1493. doi: 10.1038/s41386-021-00977-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41386-021-00977-9</ArticleId><ArticleId IdType="pmc">PMC8209059</ArticleId><ArticleId IdType="pubmed">33658653</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>